The Melasma Dialogue: Setting Expectations Before Treatment
In this special conference coverage from the 2026 Elevate-Derm RAPIDS Conference, host Eileen Cheever, PA, sat down with Heather Woolery-Lloyd, MD, to unpack her lectures on immunology and emerging therapies for vitiligo and melasma. Woolery-Lloyd opened with what she calls the "melasma dialogue" — a counseling framework she treats as just as important as the treatment itself.
She starts by making sure patients understand that melasma is a chronic condition and that clinician and patient are working together as a team over the long term, not chasing a quick fix. Before she hands over any therapies, she emphasizes sun protection and sun avoidance. Her point to patients is blunt: if she gets them 100% clear and they walk outside for 10 minutes without protection, the melasma can come right back in 24 hours. She counsels daily sunscreen the patient actually loves and a wide-brimmed hat when outdoors.
Woolery-Lloyd also frames the reassuring part of the dialogue: melasma is largely a condition of younger patients in their 30s, 40s, and early 50s, driven by hormones, and it tends to dissipate with age. As she put it, we don't see many 80-year-olds walking around with melasma.
Hydroquinone as a Quick Fix — and the 'Hydroquinone Holiday'
Woolery-Lloyd positions hydroquinone as a quick fix rather than a long-term treatment. In her practice she uses it for four to six weeks, warning patients that they'll look great and think it's a miracle — but that the real work begins the day they stop. She then maintains with other topicals.
She stresses the "hydroquinone holiday," telling patients to keep the medication in their back pocket for when they need it, such as a flare after a lot of sun exposure or a vacation. If a patient is already on it continuously, there's no tool left to pull out, and she notes it eventually stops working with continuous use.
A practical control measure she shared: she essentially never gives refills. The rare exception is a trusted patient living outside the country, and even then maybe once a year. This keeps her in control of how much hydroquinone a patient has and avoids months of uninterrupted use.
New and Emerging Topicals and Procedures for Melasma
Woolery-Lloyd highlighted newer cosmeceutical options available in the US. Thiamidol inhibits human tyrosinase — a distinction she emphasized, since many traditional inhibitors including hydroquinone were tested on mushroom tyrosinase, which differs from the human enzyme. It comes as a serum plus day and night creams, and she often prescribes the full regimen. A second newer ingredient, 2MNG, works by binding melanin precursors and reducing both pheomelanin and eumelanin; it's available in a serum and a day cream with SPF at an affordable price point. In her clinical experience both have great safety profiles with minimal irritation and are suited for long-term maintenance.
She also flagged two agents hot off the press. Malassezin, a metabolite seen in tinea versicolor–related lightening, has been isolated for pigmentation and in a study was non-inferior to hydroquinone. Eflornithine 13%, long used for unwanted facial hair, can also help with pigment and was likewise non-inferior to hydroquinone in a comparison study. She noted she hasn't personally used the two newest agents for melasma yet, but they were well tolerated in trials.
On procedures, Woolery-Lloyd discussed recent studies using intradermal botulinum toxin injected into melasma-affected patches. In one study, the full face received a triple combination product while half the face also got intradermal botulinum toxin at baseline and week 12. After the triple combination was stopped at 12 weeks, the untreated side rebounded as expected, but the botulinum toxin–treated side continued to improve — a result she finds exciting given clinicians' existing familiarity with the toxin, though she hasn't used it this way herself.
Vitiligo: Workup, a Sunlight Tip, and Cell Suspension Transfer
For vitiligo, Woolery-Lloyd recommended a workup that goes beyond a single screen. She orders an ANA to screen for other autoimmune conditions, plus TSH and thyroid autoantibodies. Her key teaching point: patients with vitiligo have an increased risk of autoimmune thyroid disease, and a patient can be euthyroid with a normal TSH yet still have positive thyroid autoantibodies. Those antibodies are predictive of higher future risk. She emphasized this is especially valuable in pediatric patients, where the pediatrician benefits from knowing a euthyroid child carries thyroid autoantibodies.
A practical treatment tip: for patients not receiving narrowband UVB, she suggests about 10 minutes of sunlight a day — with sunscreen — to give the melanocytes a kick to restart pigment production while anti-inflammatories suppress the autoimmune driver. Practicing in Miami, she noted she gets plenty of help from the sun.
Woolery-Lloyd also described cell suspension transfer, which is FDA approved but not currently available. A postage-stamp-sized split-thickness graft from behind the ear is processed into a liquid spray of keratinocytes and melanocytes, then applied to abraded or laser-prepared vitiligo-affected skin and wrapped, with repigmentation over time. In the clinical studies, 36% of patients saw at least 80% repigmentation of the treated area. A major advantage she highlighted is the roughly 1-to-80 ratio — one small graft can treat up to 80 times its area, versus the 1-to-1 ratio of suction blister techniques.
Hidden Triggers and Oral Antioxidants for Stubborn Melasma
Closing on a panel case of a woman in her mid-60s with melasma, Woolery-Lloyd discussed oral antioxidants. She primarily uses Polypodium leucotomos, noting others such as pycnogenol pine bark extract have been described. She referenced her own double-blind, placebo-controlled trial in which patients on sunscreen plus Polypodium leucotomos showed statistically significant improvement in melasma and quality-of-life scores versus sunscreen plus placebo. She calls oral antioxidants worth considering for resistant patients.
She also urged clinicians to scrutinize medication and product lists for hidden estrogen exposure. Perimenopausal and postmenopausal hormone replacement — including topical and even intravaginal estrogen — can drive melasma, as can oral contraceptives. She cautioned about phytoestrogens in topical oils patients use on scalp or skin, citing a patient using lavender oil (which, along with tea tree oil, carries phytoestrogens and has been reported in a case of gynecomastia in young boys). When a late-60s or early-70s patient has persistent or newly worsened melasma, she recommended asking about these triggers, since patients often don't connect a new product to their flare.